CIM
ADPT icon

Contravisory Investment Management’s Adaptive Biotechnologies ADPT Stock Holding History

Contravisory Investment Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,575
Closed -$202K – 392
2026
Q1 		$202K Buy
+14,575
New +$232K 0.04% 207

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Contravisory Investment Management's ADPT Position: Q2 2026 in Review

Contravisory Investment Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 14,575 shares — an estimated $202K sold.

Contravisory Investment Management first reported a position in ADPT in Q1 2026 and held it in 1 quarter. The position peaked at $202K in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Contravisory Investment Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Contravisory Investment Management sold 14,575 Adaptive Biotechnologies shares in Q2 2026, an estimated $202K.
  • Contravisory Investment Management first reported a position in Adaptive Biotechnologies in Q1 2026 and held it in 1 quarter.
  • Contravisory Investment Management's Adaptive Biotechnologies position peaked at $202K in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.